title: Evaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: the VALIDATE-D study.
abstract: BACKGROUND
  Insufficient vitamin D status and increased renin-angiotensin system (RAS) activity have been associated with renal-vascular disease and nephropathy in diabetes. Accumulating evidence indicates that vitamin D receptor (VDR) activation lowers unfavorable RAS activity; however, more human intervention studies evaluating whether this mechanism could influence diabetic kidney disease are needed. We previously reported that both vitamin D levels and genetic variation at the VDR predict human RAS activity, and that vitamin D therapy can lower RAS activity in non-diabetics. The VALIDATE-D study is a randomized, placebo-controlled, intervention study designed to extend these findings by evaluating whether direct VDR activation in diabetes lowers circulating and local renal-vascular tissue RAS activity (Aims 1 and 2) in a manner similar to the action of ACE inhibitors (Aim 3).
  
  
  METHODS
  Forty subjects with type 2 diabetes, microalbuminuria, and without chronic kidney disease will be recruited to undergo detailed assessment of the RAS before and after randomization to calcitriol 0.75 mcg/day or placebo. Primary analyses will evaluate whether calcitriol therapy reduces circulating and renal-vascular tissue-RAS activity in comparison to placebo. All subjects will thereafter be treated with lisinopril and followed for 3.5 months to evaluate whether combination therapy (calcitriol + lisinopril vs. placebo + lisinopril) additively or synergistically improves renal-vascular function, and lowers proteinuria.
  
  
  CONCLUSIONS
  The VALIDATE-D study is the first human intervention study to evaluate whether direct VDR activation can lower the human RAS in diabetes, compared to the effect of an ACE inhibitor, and whether this mechanism can translate to clinically relevant endpoints for diabetic kidney disease. The outcomes of VALIDATE-D will have major implications for the recommendation of vitamin D supplementation for the primary prevention of kidney complications in diabetes.
  
  
  BACKGROUND
  ClinicalTrials.gov, NCT01635062.
authors: Jenifer M
authors: JM
authors: Brown
authors: Kristina
authors: K
authors: Secinaro
authors: Jonathan S
authors: JS
authors: Williams
authors: Anand
authors: A
authors: Vaidya
references: J Renin Angiotensin Aldosterone Syst. 2011 Sep;12(3):311-9
references: 21330422
references: JAMA. 2012 Nov 14;308(18):1898-905
references: 23150009
references: J Hum Hypertens. 2011 Nov;25(11):672-8
references: 21124341
references: Bone. 1997 Jun;20(6):557-62
references: 9177871
references: Ann Intern Med. 1998 Jun 15;128(12 Pt 1):982-8
references: 9625684
references: Annu Rev Pharmacol Toxicol. 2010;50:439-65
references: 20055710
references: Kidney Int. 2005 Dec;68(6):2823-8
references: 16316359
references: Nephron Exp Nephrol. 2011;117(4):e124-32
references: 20948237
references: Lancet. 2010 Jul 17;376(9736):180-8
references: 20541252
references: Metabolism. 2012 Apr;61(4):450-8
references: 22075270
references: Calcif Tissue Int. 2000 Aug;67(2):122-7
references: 10920216
references: Am J Kidney Dis. 2007 Jul;50(1):69-77
references: 17591526
references: J Clin Endocrinol Metab. 2012 Jul;97(7):2456-65
references: 22539586
references: Kidney Int. 2010 Jun;77(11):943-5
references: 20467430
references: Eur J Nutr. 2013 Oct;52(7):1771-9
references: 23262750
references: J Clin Invest. 2002 Jul;110(2):229-38
references: 12122115
references: J Clin Invest. 1985 Apr;75(4):1285-90
references: 2985655
references: Kidney Int. 2008 Jul;74(2):170-9
references: 18385669
references: Diabetologia. 2012 Mar;55(3):566-78
references: 22189484
references: Kidney Int. 2010 Jun;77(11):1000-9
references: 20182412
references: Am J Nephrol. 2004 Sep-Oct;24(5):503-10
references: 15452403
references: Hypertension. 2013 Apr;61(4):779-85
references: 23487599
references: J Clin Invest. 1974 Jul;54(1):34-42
references: 4365595
references: Clin Endocrinol (Oxf). 2011 Mar;74(3):294-9
references: 21050256
references: Clin Endocrinol (Oxf). 2011 Jun;74(6):783-90
references: 21521263
references: Hypertension. 2010 Nov;56(5):774-9
references: 20937970
references: Lancet. 2010 Nov 6;376(9752):1543-51
references: 21055801
references: Clin J Am Soc Nephrol. 2009 Jun;4(6):1128-35
references: 19443628
references: Hypertension. 2008 Aug;52(2):249-55
references: 18606901
references: Ann Intern Med. 1990 Nov 1;113(9):649-55
references: 2221645
references: Cardiorenal Med. 2011;1(3):193-210
references: 22096455
references: Curr Hypertens Rep. 2012 Apr;14(2):111-9
references: 22328068
references: J Clin Invest. 1983 Dec;72(6):2115-24
references: 6358261
references: Am J Kidney Dis. 2009 Oct;54(4):647-52
references: 19596163
references: PLoS One. 2012;7(11):e50510
references: 23209764
references: N Engl J Med. 2004 Nov 4;351(19):1941-51
references: 15516697
references: Lancet. 2007 Sep 8;370(9590):829-40
references: 17765963
references: J Clin Endocrinol Metab. 2012 Dec;97(12):4780-8
references: 22990096
references: Hypertension. 2010 May;55(5):1283-8
references: 20351344
references: Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15896-901
references: 18838678
references: N Engl J Med. 2000 Jan 20;342(3):145-53
references: 10639539
references: Kidney Int. 2013 Feb;83(2):323-30
references: 22913981
references: Am J Kidney Dis. 2013 Jul;62(1):58-66
references: 23623574
references: J Am Soc Nephrol. 2011 Jun;22(6):1122-8
references: 21527660
references: Am J Kidney Dis. 2008 May;51(5):724-31
references: 18436082